Core Viewpoint - Equinor ASA announced a cash dividend of USD 0.37 per share for the third quarter of 2025, reflecting the company's ongoing commitment to returning value to shareholders [1]. Group 1: Dividend Announcement - The cash dividend per share for Q3 2025 is set at USD 0.37 [1]. - The corresponding NOK cash dividend per share is calculated to be NOK 3.5249, based on the average USDNOK fixing rate of 9.5267 from Norges Bank [1]. - The record date for the dividend is 17 February 2026, with the payment scheduled for 27 February 2026 [2]. Group 2: Payment Details - The cash dividend will be paid to shareholders on Oslo Børs and to holders of American Depositary Receipts (ADRs) on the New York Stock Exchange [2]. - This announcement complies with the Continuing Obligations and the disclosure requirements of the Norwegian Securities Trading Act [2].

Core Insights - Exosens has exceeded its 2025 revenue guidance with a strong growth of 22.1%, reaching €468.2 million, primarily driven by robust demand in the Defense and Surveillance sectors, which accounted for 75% of total revenue [4][13] - The company has demonstrated significant profitability improvements, with adjusted EBITDA increasing by 26.6% to €151.6 million, achieving a sector-leading margin of 32.4% [4][35] - Exosens is targeting continued double-digit growth in 2026, with projected revenue between €520 million and €540 million and adjusted EBITDA between €168 million and €178 million [46][52] Financial Performance - Revenue for 2025 was €468.2 million, up from €383.4 million in 2024, reflecting a 22.1% increase [10][13] - Adjusted gross margin rose to €234.0 million, a 24.2% increase from €188.4 million in 2024, with the margin percentage improving to 50.0% [31][10] - Net profit from continued operations more than doubled to €70.2 million, a 106.0% increase compared to €34.1 million in 2024 [38][39] Business Segments - Amplification revenue reached €319.2 million, representing 68% of total sales, with an 18.4% growth driven by increased demand for night vision applications [14][13] - Detection & Imaging revenue grew by 28.0% to €150.5 million, supported by acquisitions and strong performance in Defense and Surveillance markets [21][13] - The company completed three acquisitions in 2025, enhancing its capabilities in Surveillance and expanding its technology portfolio [7][19] Market Dynamics - The Defense sector is experiencing heightened demand for night vision technologies, particularly due to geopolitical tensions and evolving military requirements [15][16] - Exosens has secured significant contracts, including a €500 million deal with OCCAR for supplying night vision tubes to the German armed forces [16][7] - The company is investing €37 million to expand production capacity by 40% by 2027, targeting growth in both European and U.S. markets [17][46] Innovation and R&D - Exosens launched a breakthrough 5G image intensifier tube, improving performance benchmarks in night vision technology [18][7] - R&D expenses increased by 19.8% to €35.7 million, reflecting the company's commitment to innovation in imaging technologies [41][10] - The company is focused on developing advanced imaging systems for various sectors, including Defense, Industrial Control, Life Sciences, and Nuclear [41][7] Strategic Outlook - Exosens aims for medium-term organic revenue growth in the mid-teens and adjusted EBITDA growth above 15% [48][47] - The company plans to maintain a disciplined approach to capital allocation, focusing on long-term value creation through targeted acquisitions [50][51] - A proposed cash dividend of €0.30 per share for the 2025 fiscal year reflects the company's commitment to returning value to shareholders [45][51]

Core Insights - Novartis will present data on Rhapsido (remibrutinib), a selective oral Bruton's tyrosine kinase inhibitor, at the AAAAI Annual Meeting, focusing on its use in chronic spontaneous urticaria (CSU) and potential for peanut allergy treatment [1][2][3] Group 1: Clinical Data and Trials - New analyses from Phase III REMIX-1 and REMIX-2 trials will be presented, highlighting Rhapsido's impact on disease control and early symptom relief in CSU [2][6] - The first Phase II data on remibrutinib for IgE-mediated peanut allergy will be featured, with plans for a Phase III program in food allergy set for 2026 [2][3][6] - Positive topline results from the CIndU Phase III RemIND trial were announced, with FDA submission for symptomatic dermographism completed in Q4 2025 [4] Group 2: Regulatory and Market Potential - Regulatory reviews for remibrutinib in CSU are ongoing in regions including the European Union and Japan, indicating a strong commitment to expanding its market presence [3][4] - Novartis aims to address unmet needs in immune-mediated diseases, emphasizing the importance of innovative therapies for patients with limited alternatives [3][4] Group 3: Presentation Details - Accepted abstracts for presentation at the AAAAI include studies on the efficacy and safety of remibrutinib for peanut allergy and analyses from the REMIX studies on CSU [5][6] - Specific presentation times and formats are outlined, including oral and poster sessions scheduled from February 27 to March 1, 2026 [5][6]

Core Viewpoint - argenx is actively engaging in the healthcare sector by participating in conferences to discuss advancements in immunology and its commitment to treating severe autoimmune diseases [1]. Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3]. - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3]. - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, exploring its potential across multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines [3]. Event Participation - Karen Massey, the Chief Operating Officer of argenx, will participate in a fireside chat at the TD Cowen 46 Annual Healthcare Conference on March 2 at 11:50 a.m. ET [1]. - A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days following the event [2].

Core Viewpoint - WISeKey International Holding Ltd is relocating its headquarters from Geneva to Pont-Rouge in August 2026, aiming to enhance its position in the digital and quantum technology sectors [3][12]. Group 1: Relocation Details - The new headquarters will be situated in Pont-Rouge, a modern and sustainable business district completed in 2023, which offers exceptional connectivity and a vibrant ecosystem for innovation [4][5]. - Pont-Rouge spans over 100,000 m² and includes premium office facilities, co-working spaces, and iconic buildings, already hosting major firms like EY and KPMG [5]. Group 2: Geneva Quantum Center of Excellence - The headquarters will house the Geneva Quantum Center of Excellence, aimed at establishing Geneva as a global leader in applied quantum technologies [6][12]. - The Center will integrate various technologies including quantum computing, cybersecurity, and AI, creating a comprehensive ecosystem for industrial applications [6][12]. Group 3: SEALSQ Quantum Computer Hub - The Quantum Computer Hub, operated by WISeKey's subsidiary SEALSQ Corp, will focus on practical quantum architectures for secure integration into critical infrastructures across various sectors [7]. - The hub will emphasize hybrid quantum/classical computing models and secure interfaces between quantum processors and embedded systems [8]. Group 4: SEALSQ Quantum Fund - The SEALSQ Quantum Investment Fund, with over USD 100 million, aims to build a root-to-quantum vertical stack and accelerate the deployment of secure quantum technologies in the US and Europe [10]. - The fund's strategy seeks to eliminate fragmentation in the quantum value chain, promoting sovereign and certifiable quantum solutions [11]. Group 5: Strategic Commitment - The relocation and establishment of the Geneva Quantum Center of Excellence reflect WISeKey and SEALSQ's commitment to technological sovereignty in Europe and the development of trusted digital infrastructures [12][16].

Core Viewpoint - WISeKey International Holding Ltd is relocating its headquarters from Geneva to Pont-Rouge in August 2026, aiming to enhance its position in the digital and quantum technology sectors [3][12]. Group 1: Relocation Details - The new headquarters will be situated in Pont-Rouge, a modern and sustainable business district completed in 2023, which offers exceptional connectivity and a vibrant ecosystem for innovation [4][5]. - Pont-Rouge spans over 100,000 m² and includes premium office facilities, co-working spaces, and iconic buildings, already hosting major firms like EY and KPMG [5]. Group 2: Geneva Quantum Center of Excellence - The headquarters will house the Geneva Quantum Center of Excellence, aimed at establishing Geneva as a global leader in applied quantum technologies [6][12]. - The Center will integrate various technologies including quantum computing, cybersecurity, and AI, creating a comprehensive ecosystem for industrial applications [6][12]. Group 3: SEALSQ Quantum Computer Hub - The Quantum Computer Hub, operated by WISeKey's subsidiary SEALSQ Corp, will focus on practical quantum architectures for secure integration into critical infrastructures across various sectors [7]. - The hub will emphasize hybrid quantum/classical computing models and secure interfaces between quantum processors and embedded systems [8]. Group 4: SEALSQ Quantum Fund - The SEALSQ Quantum Investment Fund, with over USD 100 million, aims to build a root-to-quantum vertical stack and accelerate the deployment of secure quantum technologies in the US and Europe [10]. - The fund's strategy seeks to eliminate fragmentation in the quantum value chain, promoting sovereign and certifiable quantum solutions [11]. Group 5: Strategic Commitment - The relocation and establishment of the Geneva Quantum Center of Excellence reflect WISeKey and SEALSQ's commitment to technological sovereignty in Europe and the development of trusted digital infrastructures [12][16]. - The initiative aligns with Geneva's role in sustainable innovation and human-centric technology, focusing on security, trust, and ethics [16].

Core Insights - SEALSQ Corp and WISeKey International Holding Ltd are relocating their Geneva headquarters to Pont-Rouge in August 2026, reflecting their rapid expansion and ambition in digital and quantum technologies [3][12] - The new headquarters will host the Geneva Quantum Center of Excellence, aimed at establishing Geneva as a global reference for applied quantum technologies [6][12] Company Overview - SEALSQ specializes in developing and selling semiconductors, PKI, and post-quantum technology hardware and software products [3][13] - The company is focused on creating post-quantum semiconductors that provide robust protection for sensitive data across various applications, including healthcare, defense, and IoT [14][17] Quantum Center of Excellence - The Geneva Quantum Center of Excellence will serve as a deep-tech convergence platform, integrating quantum computing, post-quantum cybersecurity, and other advanced technologies [6][10] - The center will feature a live demonstration environment showcasing the interoperability of the group's technologies across different domains [9] Quantum Investment Fund - The SEALSQ Quantum Investment Fund, with over USD 100 million, aims to build a root-to-quantum vertical stack and accelerate the deployment of secure quantum technologies in the U.S. and Europe [10][11] - The fund's strategy focuses on eliminating fragmentation between research, hardware, and deployment to create scalable quantum solutions [11] Strategic Commitment - The relocation and establishment of the Geneva Quantum Center of Excellence highlight SEALSQ and WISeKey's commitment to technological sovereignty in Europe and the development of trusted digital infrastructures [12][16]

Core Insights - AGIBOT is expanding its presence in Singapore following its market entry in 2025, focusing on understanding local industry needs and exploring collaboration opportunities [1][2][10] Group 1: Market Engagement - AGIBOT participated in a Chinese New Year event on February 11, 2026, showcasing its robotics portfolio, including a robotic dog demonstration, to local business and professional communities [2][4] - The company engaged in a blessing ceremony at Sentosa on February 17, 2026, and showcased humanoid robotics in a hospitality environment, allowing guests to observe system design and mobility features [3][7] Group 2: Strategic Collaborations - AGIBOT featured its robotics technology at Changi Airport Terminal 5 in collaboration with Certis Group, assessing robotics integration in high-security and high-traffic environments [5] - The company is exploring diversified market approaches, including joint ventures, leasing collaborations, and establishing a regional experience center for technical demonstrations and enterprise training [9] Group 3: Deployment Strategy - AGIBOT is adopting a phased deployment strategy in Singapore, focusing on controlled testing, operational feedback, and local collaboration to ensure long-term sustainability of humanoid robotics applications [8] - The company shipped over 5,100 humanoid robots globally in 2025, ranking first in the world, reflecting its industrial-scale production capability and expanding international footprint [6]

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly providing misleading information regarding its financial targets and growth potential during the specified Class Period from February 25, 2025, to February 2, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that PayPal's management provided overly optimistic statements about the company's growth potential and its ability to execute on these targets, while concealing adverse facts about the salesforce's readiness [5]. - Investors who purchased PayPal common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 20, 2026, to represent the interests of the class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements including securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Enphase Energy, Inc. securities for the period between April 22, 2025, and October 28, 2025, due to alleged misleading statements and failure to disclose critical information [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Enphase overstated its ability to manage channel inventory and mitigate the effects of the termination of the Residential Clean Energy Credit, leading to materially false and misleading public statements [5]. - Investors who purchased Enphase securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by April 20, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].